McKesson (NYSE:MCK) Price Target Increased to $182.00 by Analysts at Morgan Stanley

Share on StockTwits

McKesson (NYSE:MCK) had its price objective increased by Morgan Stanley from $168.00 to $182.00 in a research report sent to investors on Tuesday morning, BenzingaRatingsTable reports. Morgan Stanley currently has an overweight rating on the stock.

MCK has been the subject of a number of other reports. Robert W. Baird raised McKesson from a neutral rating to an outperform rating and raised their price objective for the stock from $164.00 to $197.00 in a research report on Friday, February 7th. UBS Group downgraded McKesson to a sell rating and set a $147.00 price objective for the company. in a research report on Thursday, January 9th. Barclays reissued a hold rating and set a $170.00 price objective on shares of McKesson in a research report on Sunday, January 19th. Deutsche Bank raised their price objective on McKesson from $153.00 to $173.00 and gave the stock a hold rating in a research report on Wednesday, February 5th. Finally, TheStreet downgraded McKesson from a b rating to a c- rating in a research report on Wednesday, October 30th. Three investment analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. The stock currently has a consensus rating of Hold and a consensus target price of $162.80.

Shares of MCK opened at $168.03 on Tuesday. McKesson has a 52-week low of $110.52 and a 52-week high of $169.67. The company has a market capitalization of $29.73 billion, a PE ratio of -34.36, a price-to-earnings-growth ratio of 1.56 and a beta of 1.16. The stock has a fifty day simple moving average of $148.49 and a two-hundred day simple moving average of $143.71. The company has a quick ratio of 0.56, a current ratio of 0.98 and a debt-to-equity ratio of 1.33.

McKesson (NYSE:MCK) last issued its earnings results on Tuesday, February 4th. The company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.56 by $0.25. McKesson had a positive return on equity of 36.40% and a negative net margin of 0.41%. The business had revenue of $59.17 billion during the quarter, compared to the consensus estimate of $59.10 billion. During the same period last year, the company earned $3.40 EPS. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, equities analysts anticipate that McKesson will post 14.73 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Investors of record on Monday, March 2nd will be given a dividend of $0.41 per share. This represents a $1.64 dividend on an annualized basis and a dividend yield of 0.98%. The ex-dividend date is Friday, February 28th. McKesson’s payout ratio is 12.09%.

In related news, CEO Brian S. Tyler sold 4,062 shares of the firm’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $153.68, for a total transaction of $624,248.16. Following the completion of the sale, the chief executive officer now directly owns 16,254 shares of the company’s stock, valued at approximately $2,497,914.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.88% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Venturi Wealth Management LLC purchased a new position in McKesson during the 3rd quarter valued at about $27,000. Usca Ria LLC purchased a new position in shares of McKesson in the 3rd quarter valued at about $27,000. Prime Capital Investment Advisors LLC purchased a new position in shares of McKesson in the 3rd quarter valued at about $27,000. Penserra Capital Management LLC boosted its stake in shares of McKesson by 55.6% in the 4th quarter. Penserra Capital Management LLC now owns 210 shares of the company’s stock valued at $30,000 after buying an additional 75 shares during the period. Finally, Keebeck Wealth Management LLC purchased a new position in shares of McKesson in the 4th quarter valued at about $29,000. Institutional investors own 87.09% of the company’s stock.

About McKesson

McKesson Corporation provides pharmaceuticals and medical supplies in the United States and internationally. It operates in three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, as well as other healthcare-related products; and offers practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices.

Further Reading: Asset Allocation, Balancing Your Investments

Analyst Recommendations for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

ConocoPhillips  Receives New Coverage from Analysts at Capital One Financial
ConocoPhillips Receives New Coverage from Analysts at Capital One Financial
First Trust Advisors LP Sells 44,114 Shares of H & R Block Inc
First Trust Advisors LP Sells 44,114 Shares of H & R Block Inc
CoreSite Realty  Downgraded by Bank of America
CoreSite Realty Downgraded by Bank of America
Regeneron Pharmaceuticals  Lifted to Buy at Argus
Regeneron Pharmaceuticals Lifted to Buy at Argus
First Trust Advisors LP Has $11.05 Million Stock Holdings in Alliance Data Systems Co.
First Trust Advisors LP Has $11.05 Million Stock Holdings in Alliance Data Systems Co.
QAD  Upgraded by Zacks Investment Research to Buy
QAD Upgraded by Zacks Investment Research to Buy


 
© 2006-2020 Zolmax.